


Study	Disease	Total (n)	% increased thickness
Genc 2004	Control	20	5
Xie 2019	Control	20	5
Wervers 2018	Control	25	0
Ebstein 2017	Control	26	5.7
Woodburn 2013	Control	29	0
Ishida 2019	Control	30	25
Bandinelli 2010	Control	40	0
Bandinelli 2013	Control	40	0
Ursini 2017	Control	40	8.8
Tom 2019	Control	50	10
Guldberg-Møller 2018	Control	64	9
Matteo 2018	Control	65	9.2
Ezzat 2012	PsA	10	70
Perrotta 2016	PsA	21	33.3
Wervers 2018	Early PsA	25	8
Wervers 2018	Established PsA	25	26
Ahmed 2017	PsA	35	34.5
Woodburn 2013	PsA	42	19
Michelson 2017*	PsA*	44	11.4
Matteo 2018	PsA	50	24
Tom 2019	PsA	50	16
Xie 2019	Early PsA	60	31.67
Fiorenza 2020	PsA+Fibromyalgia	78	8
Bandinelli 2013	PsA	92	33.5
Michelson 2017	PsA	97	13.9
Macchioni 2019	PsA	140	22.9
Feydy 2012	SpA*	13	31.58
McGonagle 2008*	SpA*	20	80
Seven 2020	SpA	21	14
Feydy 2012	SpA	25	7.02
Balint 2002	SpA	35	20
Baccouche 2018	SpA	40	5.6
Ebstein 2017	SpA	41	12.2
Witrand 2017	SpA	402	10.2
Ezzat 2012	AS	10	60
Genc 2004	AS	18	67
Ishida 2019	AS	50	36
Ezzat 2012	ReA	10	60
Ezzat 2012	IBD related	15	20
Bandinelli 2010	IBD related	81	9.9
Matteo 2018	SLE	65	9.2
Genc 2004	RA	24	42
Ebstein 2017	RA	30	10
Baccouche 2018	LBP	20	2.5
Fiorenza 2020	Fibromyalgia	23	2.6
Feydy 2012	LBP	24	9.38
Ursini 2017	T2DM	43	24.4
Hussein 2014	CKD	50	18
Macchioni 2019	Fibromyalgia	51	3.9

**Supplementary Table S1.** Studies with thickness noted at the Achilles enthesis.

Control: healthy controls per study description; PsA: psoriatic arthritis; SpA: spondyloarthropathy; ReA: reactive arthritis; AS: ankylosing Spondylitis; IBD: inflammatory bowel disease; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; DM: diabetes mellitus.

Studies arranged in order of lowest to highest (n) in each disease category.


* Indicates a study focusing only on symptomatic tendons in underlying inflammatory disease.

**Supplementary Table S2.** Studies with Doppler signal noted at the Achilles enthesis.

Control: healthy controls per study description; PsA: psoriatic arthritis; SpA: spondyloarthropathy; ReA: reactive arthritis; AS: ankylosing Spondylitis; IBD: inflammatory bowel disease; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; DM: diabetes mellitus.

Studies arranged in order of lowest to highest (n) in each disease category.

* Indicates a study focusing only on symptomatic tendons in underlying inflammatory disease.

**Supplementary Table S3.** Studies with erosions noted at the Achilles enthesis.

Control: healthy controls per study description; PsA: psoriatic arthritis; SpA: spondyloarthropathy; ReA: reactive arthritis; AS: ankylosing Spondylitis; IBD: inflammatory bowel disease; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; DM: diabetes mellitus.

Studies arranged in order of lowest to highest (n) in each disease category.

Supplementary Table S4. Characteristics of included studies (looking at thickness as a parameter).

Author	Population	Participant demographics	Mean age (std dev) [range]	BMI (std dev)	Criteria
Ahmed 2017	PsA	n=35 (20M/15F)	44.77 (10.11)	26.42 (4.8)	PA
Baccouche 2018	SpA Mechanical LBP	n=40 (12F/28M)	41.9 (14.3)	NR	OMERACT
		n=20 (16F/4M)	51.1 (11.5)	NR	
Balint 2002	SpA	n=35 (10F/25M)	48 (14)	NR	GUESS
Bandinelli 2010	IBD-associated HC	n=81 (43F/38M)	41.3 (12.3) [18-68]	22 (3.1)	GUESS
		n=40 (22F/18M)	49.6 (11.1)	24 (2)	
Bandinelli 2013	PsA HC	n=92 (51F/41M)	51.6 (15.4)	22 (2.6)	GUESS
		n=40 (22F/18M)	49.6 (11.1)	24 (2)	
Comin 2012	Ballet Dancers	n=79 (44F/35M)	M: 28.7 (5.8)/F:26.4 (6.6)	NR	PA
Ebstein 2017	RA	n=30 (25F/5M)	55.7 (14.8)	NR	GUESS, MASEI
	SpA	n=41 (13F/28M)	45.3 (15.4)	NR	
	HC	n=26 (17F/9M)	50.4 (17.3)	NR	
Ezzat 2012	PsA	n=10 (22F/23M for whole group)	50.9 (13.3)	NR	GUESS
	AS	n=10	30.2 (2.9)	NR	
	ReA	n=10	27.8 (6.4)	NR	
	IBD-associated	n=15	UC-31.8 (7.1)/ Crohns- 37.6 (4.8)	NR	
Feydy 2012	Asymptomatic SpA	n=25 (12F/13M)	45	NR	PA
	SpA with heel pain	n=13 (3F/10M)	43	NR	
	Mechanical LBP	n=24 (12F/12M)	50	NR	
Fiorenza 2020	Fibromyalgia	n=23 (22F/1M)	49 (IQR 20)	28.12 (6.38)	OMERACT
	PsA+Fibromyalgia	n=78 (61F/17M)	PsA- 56 (IQR 9); PsA+ Fibromyalgia- 53 (IQR 10)	PsA- 28.58 (6.75); PsA+ Fibromyalgia- 28.58 (4.48)	
Genc 2004	HC	n=20 (15F/5M)	42.6 (10.51) [28-61]	26.78 (3.16)	GUESS
	RA	n=24 (22F/2M)	44.37 (7.44) [32-62]	25.6 (3.45)	
	AS	n=18 (4F/14M)	41.38 (8.49) [29-60]	26.46 (3.67)	
Guldberg-Moller 2018	HC	n=64 (32F/32M)	39.8 (IQR 30.2, 49.7)	24.1 (3.7)	OMERACT
Huang 2011	AS- group 1	n=5 (0F/5M)	NR	30.8 (8.1)	GUESS
	AS- group 2	n=7 (1F/6M)	NR	23.1 (5.5)	
Hussein 2014	CKD	n=50 (27F/23M)	51.58 (12.5)	NR	PA
Ishida 2019	AS	n=50 (10F/40M)	43.44 (9.91)	25.2 (4.93)	MASEI
	HC	n=30 (7F/23M)	38.7 (8.52)	26.92 (10.01)	
Leung 2007	AT	n=21 (12F/9M)	49.6 (14.6)	NR	PA
	HC	n=50 (28F/22M)	43.2 (14.1)	NR	
Macchioni 2019	PsA	n=140 (70F/70M)	48 [40-58]	25.6 [22-29]	GUESS
	PsO	n=51 (28F/23M)	51 [44-57]	27.1 [24.3-30.4]	
	FMS	n=51 (47F/4M)	50 [42-57]	23.4 [21.5-24.7]	
Matteo 2018	SLE	n=65 (60F/5M)	41.8 (14)	23.5 (4)	OMERACT
	PsA	n=50	NR	NR	
	HC	n=50	NR	NR	
McGonagle 2008	Early SpA	n=20 (8F/12M)	43 [26-64]	NR	OMERACT
	Chronic SpA	n=17 (8F/9M)	52.8 [27-70]	NR	
Michelson 2017	PsA	n=141 (71F/70M)	52.4 (10.2)	28.3 (4.3)	OMERACT
Mutlu 2020	CKD	n=30 (13F/17M)	46.7 (16)	NR	PA
	HC	n=30 (11F/19M)	52.8 (11)	NR	
Perrotta 2016	PsA	n=21 (7F/14M)	50.2 (12.4)	NR	OMERACT
Ryan 2010	AT	n=22 tendons	54 (10.8)	NR	PA
Seven 2020	SpA	n=21 (9F/12M)	39.4 (9.4)	NR	OMERACT
Tom 2019	PsA	n=50 (20F/30M)	55 (12.2)	28.9 (4.8)	OMERACT
	HC	n=50 (21F/29M)	55.1 (8.3)	24.7 (3.8)	
Ursini 2017	T2DM	n=43 (18F/25M)	60.8 (9.4)	29.2 (4.8)	PA
	HC	n=40 (19F/21M)	58.4 (7.0)	28.6 (3.7)	
Wervers 2018	PsA (early)	n=25 (12F/13M)	50 [30-72]	NR	MASEI
	PsA (established)	n=25 (12F/13M)	44 [26-53]	NR	
	HC	n=25 (13F/12M)	22 [20-26]	NR	
Witrand 2017	SpA	n=402 (207F/195M)	33.5 [26.7-39.4]	NR	OMERACT
Woodburn 2012	PsA	n=42 (25F/17M)	45.3 (12.7)	NR	GUESS
	HC	n=29 (18F/11M)	40 (10.5)	NR	
Xie 2019	PsA (early)	n=60 (27F/33M)	43.4 (15.2)	22.6 (2.6)	GUESS
	PsO	n=100 (45F/55M)	43.5 (18.1)	23.1 (2.3)	
	HC	n=20 (9F/11M)	42.4 (16.7)	22.5 (3.4)	
Zuliani 2019	HC	n=20 (12F/8M)	47 (16)	24 (4.3)	OMERACT

PA: specified within the article; BUSES: Belgrade Ultrasound Enthesitis Score; GUESS: Glasgow Ultrasound Enthesitis Scoring System; MASEI: Madrid Sonography Enthesitis Index; OMERACT: Outcome Measure in Rheumatology Ultrasound Working Group.

Supplementary Table S5. Characteristics of included studies (looking at vascularity as a parameter).

Author	Population	Participant demographics	Mean age (std dev) [range]	BMI (std dev)	Criteria
Abate 2014	AT HC	n=45 (16F/29M) n=45 (16F/29M)	57.4 (4.2) 58.1 (5.1)	25.9 (3) 23.8 (2.8)	GUESS
Baccouche 2018	SpA Mechanical LBP	n=40 (12F/28M) n=20 (16F/4M)	41.9 (14.3) 51.1 (11.5)	NR NR	OMERACT
Bandinelli 2010	IBD-associated HC	n=81 (43F/38M) n=40 (22F/18M)	41.3 (12.3) [18-68] 49.6 (11.1)	22 (3.1) 24 (2)	GUESS
Bandinelli 2013	PsA HC	n=92 (51F/41M) n=40 (22F/18M)	51.6 (15.4) 49.6 (11.1)	22 (2.6) 24 (2)	GUESS
Boesen 2012	AT (badminton players)	n=86 (30F/56M)	21.7 (5)	22.8 (2.4)	PA
Ebstein 2017	RA SpA HC	n=30 (25F/5M) n=41 (13F/28M) n=26 (17F/9M)	55.7 (14.8) 45.3 (15.4) 50.4 (17.3)	NR NR NR	GUESS, MASEI
Feydy 2012	Asymptomatic SpA SpA with heel pain Mechanical LBP	n=25 (12F/13M) n=13 (3F/10M) n=24 (12F/12M)	45 43 50	NR NR NR	PA
Fiorenza 2020	PsA+Fibromyalgia Fibromyalgia	n=78 (61F/17M) n=23 (22F/1M)	PsA- 56 (IQR 9); PsA+ Fibromyalgia- 53 (IQR 10) 49 (IQR 20)	PsA- 28.58 (6.75); PsA+ Fibromyalgia- 28.58 (4.48) 28.12 (6.38)	OMERACT*
Guldberg-Moller 2018	HC	n=64 (32F/32M)	39.8 (IQR 30.2, 49.7)	24.1 (3.7)	OMERACT*
Hamdi 2010	AS	n=60 (12F/48M)	36(11) [20-74]	NR	PA
Harman 2017	SpA RA HC	n=40 (19F/21M) n=27 (14F/13M) n=15 (0F/15M)	43.37 (9.55) 45.63 (11.76) 42.13 (4.93)	27.52 (3.95) 27.18 (5.23) 26.47 (3.65)	MASEI
Huang 2011	AS- group 1 AS- group 2	n=5 (0F/5M) n=7 (1F/6M)	NR NR	30.8 (8.1) 23.1 (5.5)	GUESS
Ishida 2019	AS HC	n=50 (10F/40M) n=30 (7F/23M)	43.44 (9.91) 38.7 (8.52)	25.2 (4.93) 26.92 (10.01)	MASEI
Li 2010	AS ReA SpA PsA	n=50 (12F/38M) n=10 (7F/3M) n=5 (2F/3M) n=5 (2F/3M)	33 (10) 34 (9) 35 (11) 50 (16)	NR NR NR NR	PA
Macchioni 2019	PsA PsO FMS	n=140 (70F/70M) n=51 (28F/23M) n=51 (47F/4M)	48 [40-58] 51 [44-57] 50 [42-57]	25.6 [22-29] 27.1 [24.3-30.4] 23.4 [21.5-24.7]	GUESS
Mallarias 2008	AT	n=13 (7F/6M)	40 [25-57]	NR	PA
Matteo 2018	SLE PsA HC	n=65 (60F/5M) n=50 n=50	41.8 (14) NR NR	23.5 (4) NR NR	OMERACT*
Michelson 2017	PsA	n=141 (71F/70M)	52.4 (10.2)	28.3 (4.3)	OMERACT*
Perrotta 2016	PsA	n=21 (7F/14M)	50.2 (12.4)	NR	OMERACT
Pistone 2015	PsA	n=30	NR	NR	GUESS
Ryan 2010	AT	n=22 tendons	54 (10.8)	NR	PA
Seven 2020	SpA	n=21 (9F/12M)	39.4 (9.4)	NR	OMERACT*
Tom 2019	PsA HC	n=50 (20F/30M) n=50 (21F/29M)	55 (12.2) 55.1 (8.3)	28.9 (4.8) 24.7 (3.8)	OMERACT*
Ursini 2017	T2DM HC	n=43 (18F/25M) n=40 (19F/21M)	60.8 (9.4) 58.4 (7.0)	29.2 (4.8) 28.6 (3.7)	PA
Weill 2013	SpA AT HC	n=12 (9F/3M) n=15 (5F/10M) n=10 (6F/4M)	38.5 [27-59] 47 [31-60] 41.5 [35-58]	NR NR NR	PA
Wervers 2018	PsA (early) PsA (established) HC	n=25 (12F/13M) n=25 (12F/13M) n=25 (13F/12M)	50 [30-72] 44 [26-53] 22 [20-26]	NR NR NR	MASEI
Witrand 2017	SpA	n=402 (207F/195M)	33.5 [26.7-39.4]	NR	OMERACT*
Woodburn 2012	PsA HC	n=42 (25F/17M) n=29 (18F/11M)	45.3 (12.7) 40 (10.5)	NR NR	GUESS
Xie 2019	PsA (early) PsO HC	n=60 (27F/33M) n=100 (45F/55M) n=20 (9F/11M)	43.4 (15.2) 43.5 (18.1) 42.4 (16.7)	22.6 (2.6) 23.1 (2.3) 22.5 (3.4)	GUESS

PA: specified within the article; BUSES: Belgrade Ultrasound Enthesitis Score; GUESS: Glasgow Ultrasound Enthesitis Scoring System; MASEI: Madrid Sonography Enthesitis Index; OMERACT: Outcome Measure in Rheumatology Ultrasound Working Group (Wakefield 2005).

OMERACT*: updated Outcome Measure in Rheumatology Ultrasound Working Group criteria utilising Doppler signal at <2mm from enthesis (Balint 2018, Terslev 2014)

Supplementary Table S6. Characteristics of included studies (looking at erosions as a parameter).

Author	Population	Participant demographics	Mean age (std dev) [range]	BMI (std dev)	Criteria
Abate 2014	AT HC	n=45 (16F/29M) n=45 (16F/29M)	57.4(4.2) 58.1(5.1)	25.9(3) 23.8(2.8)	GUESS
Ahmed 2017	PsA	n=35 (20M/15F)	44.77 (10.11)	26.42(4.8)	PA
Baccouche 2018	SpA Mechanical LBP	n=40 (12F/28M) n=20 (16F/4M)	41.9(14.3) 51.1(11.5)	NR NR	OMERACT
Balint 2002	SpA	n=35 (10F/25M)	48 (14)	NR	GUESS
Bandinelli 2010	IBD-associated HC	n=81 (43F/38M) n=40 (22F/18M)	41.3 (12.3) [18-68] 49.6 (11.1)	22 (3.1) 24 (2)	GUESS
Bandinelli 2013	PsA HC	n=92 (51F/41M) n=40 (22F/18M)	51.6 (15.4) 49.6 (11.1)	22 (2.6) 24 (2)	GUESS
Ebstein 2017	RA SpA HC	n=30 (25F/5M) n=41 (13F/28M) n=26 (17F/9M)	55.7(14.8) 45.3(15.4) 50.4(17.3)	NR NR NR	GUESS, MASEI
Feydy 2012	Asymptomatic SpA SpA with heel pain Mechanical LBP	n=25 (12F/13M) n=13 (3F/10M) n=24 (12F/12M)	45 43 50	NR NR NR	PA
Fiorenza 2020	PsA+Fibromyalgia Fibromyalgia	n=78 (61F/17M) n=23 (22F/1M)	PsA- 56 (IQR 9); PsA+ Fibromyalgia- 53 (IQR 10) 49 (IQR 20)	PsA- 28.58 (6.75); PsA+ Fibromyalgia- 28.58 (4.48) 28.12 (6.38)	OMERACT
Genc 2004	RA AS HC	n=24 (22F/2M) n=18 (4F/14M) n=20 (15F/5M)	44.37 (7.44) [32-62] 41.38 (8.49) [29-60] 42.6 (10.51) [28-61]	25.6 (3.45) 26.46 (3.67) 26.78 (3.16)	GUESS
Guldberg-Moller 2018	HC	n=64 (32F/32M)	39.8 (IQR 30.2, 49.7)	24.1 (3.7)	OMERACT
Hamdi 2010	AS	n=60 (12F/48M)	36 (11) [20-74]	NR	PA
Harman 2017	SpA RA HC	n=40 (19F/21M) n=27 (14F/13M) n=15 (0F/15M)	43.37 (9.55) 45.63 (11.76) 42.13 (4.93)	27.52 (3.95) 27.18 (5.23) 26.47 (3.65)	MASEI
Huang 2011	AS- group 1 AS- group 2	n=5 (0F/5M) n=7 (1F/6M)	NR NR	30.8 (8.1) 23.1 (5.5)	GUESS
Ishida 2019	AS HC	n=50 (10F/40M) n=30 (7F/23M)	43.44 (9.91) 38.7 (8.52)	25.2 (4.93) 26.92 (10.01)	MASEI
Li 2010	AS SpA ReA PsA	n=50 (12F/38M) n=5 (2F/3M) n=10 (7F/3M) n=5 (2F/3M)	33 (10) 35 (11) 34 (9) 50 (16)	NR NR NR NR	PA
Macchioni 2019	PsA PsO FMS	n=140 (70F/70M) n=51 (28F/23M) n=51 (47F/4M)	48 [40-58] 51 [44-57] 50 [42-57]	25.6 [22-29] 27.1 [24.3-30.4] 23.4 [21.5-24.7]	GUESS
Matteo 2018	SLE PsA HC	n=65 (60F/5M) n=50 n=50	41.8(14) NR NR	23.5(4) NR NR	
McGonagle 2008	Early SpA Chronic SpA	n=20 (8F/12M) n=17[8F/9M]	43 [26-64] 52.8 [27-70]	NR NR	OMERACT
Michelson 2017	PsA	n=141 (71F/70M)	52.4 (10.2)	28.3 (4.3)	OMERACT
Miguel 2011	SpA	n=68 (35F/33M)	32 (7)	NR	OMERACT
Milutinovic 2017	SpA	n=76 (27F/49M)	45.7 (11.9)	NR	BUSES
Perrotta 2016	PsA	n=21 (7F/14M)	50.2 (12.4)	NR	OMERACT
Pistone 2015	PsA	n=30	NR	NR	GUESS
Serban 2020	RA HC	n=35 (30F/5M) n=35 (30F/5M)	59.2 (11.25) 58.91 (11.59)	26.49 (5.64) 25.72 (3.4)	OMERACT
Seven 2020	SpA	n=21 (9F/12M)	39.4 (9.4)	NR	OMERACT
Tom 2019	PsA HC	n=50 (20F/30M) n=50 (21F/29M)	55 (12.2) 55.1 (8.3)	28.9 (4.8) 24.7 (3.8)	OMERACT
Ursini 2017	T2DM HC	n=43 (18F/25M) n=40 (19F/21M)	60.8 (9.4) 58.4 (7.0)	29.2 (4.8) 28.6 (3.7)	PA
Weill 2013	SpA AT HC	n=12 (9F/3M) n=15 (5F/10M) n=10 (6F/4M)	38.5 [27-59] 47 [31-60] 41.5 [35-58]	NR NR NR	PA
Wervers 2018	PsA (early) PsA (established) HC	n=25 (12F/13M) n=25 (12F/13M) n=25 (13F/12M)	50 [30-72] 44 [26-53] 22 [20-26]	NR NR NR	MASEI
Witrand 2017	SpA	n=402 (207F/195M)	33.5 [26.7-39.4]	NR	OMERACT
Woodburn 2012	PsA HC	n=42 (25F/17M) n=29 (18F/11M)	45.3 (12.7) 40 (10.5)	NR NR	GUESS
Xie 2019	PsA (early) PsO HC	n=60 (27F/33M) n=100 (45F/55M) n=20 (9F/11M)	43.4 (15.2) 43.5 (18.1) 42.4 (16.7)	22.6 (2.6) 23.1 (2.3) 22.5 (3.4)	GUESS

PA: specified within the article; BUSES: Belgrade Ultrasound Enthesitis Score; GUESS: Glasgow Ultrasound Enthesitis Scoring System; MASEI: Madrid Sonography Enthesitis Index; OMERACT: Outcome Measure in Rheumatology Ultrasound Working Group.


Supplementary Table S7. Assessment of study quality using the QUADAS-2 tool for bias.


	Patient selection	Index test	Reference standard	Flow and timing
Abate 2014	Low	Unclear	Low	Unclear
Ahmed 2017	Unclear	Unclear	Unclear	Unclear
Baccouche 2018	Low	Low	Low	Low
Balint 2002	Unclear	Low	Low	Low
Bandinelli 2010	Unclear	Low	Low	Low
Bandinelli 2013	Low	Low	Low	Unclear
Boesen 2012	Low	Low	Low	Low
Comin	Unclear	Unclear	Unclear	Unclear
Ebstein 2017	Low	Low	Low	Low
Ezzat 2012	Unclear	Low	Low	Unclear
Feydy 2012	Unclear	Low	Low	Low
Fiorenza 2020	Low	Low	Low	Low
Genc 2004	Low	Low	Low	Unclear
Guldberg-Moller 2018	Low	Unclear	Unclear	Unclear
Hamdi 2010	Low	Low	Low	Low
Harman 2017	Low	Low	Low	Low
Huang 2011	Unclear	Unclear	Low	Low
Hussein 2014	Unclear	Unclear	Unclear	Low
Ishida 2019	Unclear	Low	Low	Unclear
Li 2010	Unclear	Low	Low	Low
Leung	Unclear	High	Low	Unclear
Macchioni 2019	Unclear	Low	Low	Low
Mallarias 2008	Unclear	Low	Low	Low
Matteo 2018	Low	Low	Low	Low
McGonagle 2008	Unclear	Low	Low	Low
Michelson 2017	Low	Low	Low	Low
Miguel 2011	Low	Low	Low	Low
Milutinovic 2017	Low	Low	Low	Low
Mutlu 2020	Low	Unclear	Unclear	Unclear
Perrotta 2016	Unclear	Low	Low	Low
Pistone 2015	Unclear	Unclear	Unclear	Low
Ryan 2010	Unclear	Unclear	Low	Low
Serban 2020	Low	Low	Unclear	Unclear
Seven 2020	Low	Low	Unclear	Low
Tom 2019	Unclear	Low	Unclear	Unclear
Ursini 2017	Low	Low	Low	Unclear
Weill 2013	Low	Low	Low	Low
Wervers 2018	Low	Low	Low	Unclear
Witrand 2017	Low	Low	Low	Low
Woodburn	Low	Unclear	Unclear	Unclear
Xie 2019	Unclear	Low	Low	Unclear
Zuliani 2019	Low	Low	Low	Unclear

Supplementary Table 8. Assessment of study quality using the QUADAS-2 tool for applicability.

	Patient selection	Index test	Reference standard
Abate 2014	Low	Low	Low
Ahmed 2017	Low	Low	Low
Baccouche 2018	Low	Low	Low
Balint 2002	Low	Low	Low
Bandinelli 2010	Low	Low	Low
Bandinelli 2013	Low	Low	Low
Boesen 2012	Low	Low	Low
Comin	Low	Low	Low
Ebstein 2017	Low	Low	Low
Ezzat 2012	Low	Low	Low
Feydy 2012	Low	Low	Low
Fiorenza 2020	Low	Low	Low
Genc 2004	Low	Low	Low
Guldberg-Moller 2018	Low	Low	Low
Hamdi 2010	Low	Low	Low
Harman 2017	Low	Low	Low
Huang 2011	Low	Low	Low
Hussein 2014	Low	Low	Low
Ishida 2019	Low	Low	Low
Li 2010	Low	Low	Low
Leung	Low	Low	Low
Macchioni 2019	Low	Low	Low
Mallarias 2008	Low	Low	Low
Matteo 2018	Low	Low	Low
McGonagle 2008	Low	Low	Low
Michelson 2017	Low	Low	Low
Miguel 2011	Low	Low	Low
Milutinovic 2017	Low	Low	Low
Mutlu 2020	Low	Low	Low
Perrotta 2016	Low	Low	Low
Pistone 2015	Low	Low	Low
Ryan 2010	Low	Low	Low
Serban 2020	Low	Low	Low
Seven 2020	Low	Low	Low
Tom 2019	Low	Low	Low
Ursini 2017	Low	Low	Low
Weill 2013	Low	Low	Low
Wervers 2018	Low	Low	Low
Witrand 2017	Low	Low	Low
Woodburn	Low	Low	Low
Xie 2019	Low	Low	Low

Supplementary Table S9. Comparison of abnormal thickness between control, NIT and IT.



Supplementary Table S10. Comparison of abnormal vascularity between control, NIT and IT.

Supplementary Table S11. Comparison of abnormal erosions between control, NIT and IT.

